{"denoms":[{"counts":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"115"}],"units":"Participants"}],"groups":[{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Novartis manufacturing facility in Morris Plains, US.","id":"BG000","title":"Tisagenlecleucel - Main Cohort"},{"description":"Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who received tisagenlecleucel manufactured at the Fraunhofer Institut für Zelltherapie, Leipzig, Germany.","id":"BG001","title":"Tisagenlecleucel Cohort A"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"13.09","value":"54.3"},{"groupId":"BG001","spread":"12.98","value":"51.1"},{"groupId":"BG002","spread":"13.07","value":"53.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"44"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"71"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"83"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"98"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"10"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"65"}]}],"title":"ECOG status of 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"50"}]}],"title":"ECOG status of 1"}],"description":"The Eastern Cooperative Oncology Group (ECOG) Performance status is a numbering scale used in Oncology w to define the population of patients to study in the trial and guide physicians who enroll patients into those studies. The lower the number the better the performance status of the patient, where 0: Fully active, able to carry on all pre-disease performance without restriction. ECOG Performance status of 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work.","paramType":"NUMBER","title":"ECOG performance status","unitOfMeasure":"Participants"}],"populationDescription":"Full analysis Set (FAS): Comprised all patients who received infusion of tisagenlecleucel."}